Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALAD | P13716 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934611 | 0.81 | LTB4R (0.33) | ALK | |
| SCHEMBL3932788 | 0.80 | SMYD2 (0.32) | NPSR1ALK | |
| SCHEMBL4886839 | 0.78 | SMYD2 (0.31) | — | |
| SCHEMBL9342265 | 0.77 | RXRA (0.51) | POLBHPGDRXRARXRBRXRG | |
| SCHEMBL1314001 | 0.75 | AGXT (0.42) | MAPT | |
| SCHEMBL6170674 | 0.75 | HIF1A (0.44) | HPGDABL1 | |
| SCHEMBL3936379 | 0.75 | — | — | |
| SCHEMBL3934729 | 0.75 | — | — | |
| SCHEMBL6172243 | 0.74 | MEN1 (0.38) | MAPTRXRARXRBRXRG | |
| SCHEMBL3939800 | 0.74 | SLC1A3 (0.36) | MAPTSLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | DAO 2608/4885P2RY2 2464/4885MAPT 4337/4885 |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | DAO 1959/4885P2RY2 1303/4885MAPT 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.